J Cancer Res Ther [JOURNAL]
Sun
200 papers
Application of superresolution ultrasound imaging for assessing microvascular structure and hemodynamic changes in rabbit VX2 models.
Chen C, Zeng Q, Chen S … +5 more , An S, Wan M, Zong Y, Yu J, Liang P
J Cancer Res Ther · 2025 Sep · PMID 40905873 · Publisher ↗
BACKGROUND: Noninvasive and functional tumor vascular system imaging at the microscopic scale is greatly significant. Using animal models, we investigated the feasibility of using superresolution ultrasound (SR-US) imagi...
BACKGROUND: Noninvasive and functional tumor vascular system imaging at the microscopic scale is greatly significant. Using animal models, we investigated the feasibility of using superresolution ultrasound (SR-US) imaging to visualize and quantify the microvessels during tumor growth. METHODS: This study established nine rabbit VX2 tumor models. Conventional US, contrast-enhanced US (CEUS), and SR-US images were acquired on Days 5, 8, and 14 postimplantation in 18 VX2 tumors. The imaging capabilities of CEUS and SR-US were compared, and hemodynamic changes were assessed using SR-US parameters. Pearson's correlation was calculated to analyze the association between the microvessel density (MVD) from histopathology and the vascular density (VD) from SR-US. RESULTS: SR-US demonstrated superior resolution compared with conventional CEUS. The minimum discernible vessel diameter of 105.2 ± 7.5 μm was observed in the VX2 tumor microvasculature visualized with SR-US. A strong positive correlation (r = 0.82, P = 0.006) was found between MVD and VD. The tumor size progression exhibited distinct stages: stable stage (Days 5 and 8) and growth stage (Days 8-14). Vessel pixels significantly increased throughout all experimental stages (P < 0.05), whereas both the VD and perfusion index demonstrated transient increases during the early stage before returning to baseline levels. The mean velocity and flow direction entropy initially decreased but returned to baseline later. The maximum velocity and fractal dimension significantly increased during the accelerated stage (P < 0.05). CONCLUSIONS: Quantitative SR-US parameters provided a valuable tool for assessing microvascular changes during tumor progression.
Efficacy and safety of the CT-guided co-ablation system in the treatment of malignant melanoma with hepatic metastasis.
Li X, Chen J, Nuerhashi G … +4 more , Zhang Y, Chen H, Shen L, Fan W
J Cancer Res Ther · 2025 Sep · PMID 40905872 · Publisher ↗
PURPOSE: To evaluate the efficacy and safety of computed tomography (CT)-guided co-ablation in patients with hepatic metastases from malignant melanoma. METHODS: Clinical data of 79 patients with hepatic metastases from...
PURPOSE: To evaluate the efficacy and safety of computed tomography (CT)-guided co-ablation in patients with hepatic metastases from malignant melanoma. METHODS: Clinical data of 79 patients with hepatic metastases from malignant melanoma who underwent co-ablation (integration of cryoablation and thermal ablation) and programmed death 1 (PD-1) treatment between October 2019 and January 2024 were retrospectively analyzed. The patients were divided into group A (n = 50), patients who received co-ablation, and group B (n = 29), patients who received PD-1 treatment. In group A, treatment efficacy and safety, changes in lymphocyte subsets, Th1/Th2 cell cytokines before and 3 weeks after treatment, and adverse events (AEs) during co-ablation were evaluated. RESULTS: Co-ablation exhibited favorable clinical efficacy in the treatment of hepatic metastases from malignant melanoma. The rates of complete remission (CR), partial remission (PR), progressive disease (PD), stable disease (SD), and disease control rate (DCR) were 56.0%, 24.0%, 8.0%, 12.0%, and 92.0%, respectively. In group B, the CR, PR, PD, SD, and DCR rates were 10.3%, 24.1%, 31.0%, 34.5%, and 68.9%, respectively. Three weeks after treatment, the levels of Th2-related cytokine interleukin-10, CD3-CD16 + CD56+, and CD8 + CD25 + significantly decreased compared with baseline, with group A demonstrating lower levels than group B. At the end of the follow-up, 16 patients (32%) in group A and 16 (55.2%) in group B had died. The median progression-free survival was 20.2 months in group A, which was significantly longer than the 7.93 months in group B (P = 0.005). The median overall survival in group A was 20.2 months, which was significantly longer than the 13.5 months in group B (P = 0.025). The intraoperative AEs during co-ablation included mild pain (4.0%), hepatic arterial bleeding (2.0%), minor subcapsular bleeding (4.0%), minor pneumothorax (4.0%), and vomiting (2.0%). CONCLUSION: The CT-guided co-ablation system exhibited favorable clinical efficacy and was associated with a low incidence of AEs in the treatment of hepatic metastases from malignant melanoma, indicating its potential clinical value.
Improvement and application of supine position components for lung tumor microwave ablation.
Zhang Y, Li Y, Wei Q … +6 more , Liu J, Peng H, Gao X, Lu D, Xu Z, Yang N
J Cancer Res Ther · 2025 Sep · PMID 40905871 · Publisher ↗
OBJECTIVE: This study aimed to evaluate the safety and efficacy of improved supine positioning components for lung tumor microwave ablation (MWA), with the goal of enhancing surgical efficiency, reducing complications, a...
OBJECTIVE: This study aimed to evaluate the safety and efficacy of improved supine positioning components for lung tumor microwave ablation (MWA), with the goal of enhancing surgical efficiency, reducing complications, and improving patient experience. MATERIALS AND METHODS: One hundred patients undergoing MWA for lung tumors were randomly divided into two groups (n = 50 each): experimental (using improved components) and control (using traditional components). The improved positioning system included a high-density memory foam head pillow, lumbar and leg pillows, and adjustable fixing bands tailored to individual patient needs. A comparative analysis was performed on the positioning time, surgical localization time, number of intraoperative computed tomography (CT) scans, changes in vital signs, incidence of postoperative complications, and patient satisfaction between the groups. RESULTS: The experimental group showed significantly shorter positioning (9.48 ± 1.79 min) and surgical localization times (15.08 ± 2.76 min) compared to the control group (P < 0.05). They also required fewer intraoperative CT scans and exhibited more efficient surgical procedures. The experimental group demonstrated a smaller fluctuation range in vital signs and a significantly lower incidence of hypoxemia (P < 0.05), indicating enhanced intraoperative safety in the experimental group. Additionally, the experimental group showed lower pneumothorax and hemothorax rates and higher postoperative patient satisfaction scores (P < 0.05). CONCLUSION: The use of improved positioning components during MWA for lung tumors effectively reduces positioning time, improves surgical efficiency, lowers intraoperative complication risks, and enhances patient satisfaction. Thus, their application may be recommended for lung tumor MWA.
What is the optimal first-line regimen for patients with advanced HER2-positive breast cancer: A systematic review and network meta-analysis.
Wei C, Zheng Q, Ma X … +5 more , Sun X, Wang Z, Tang S, Liu Y, Wang X
J Cancer Res Ther · 2025 Sep · PMID 40905870 · Publisher ↗
BACKGROUND: The advent of anti-HER2 agents, such as trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1), has significantly improved survival in metastatic HER2-positive breast cancer (BC). Multiple anti-HER2 combi...
BACKGROUND: The advent of anti-HER2 agents, such as trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1), has significantly improved survival in metastatic HER2-positive breast cancer (BC). Multiple anti-HER2 combination regimens are recommended as first-line treatments, but the optimal choice remains unclear. This study aimed to determine the optimal first-line regimen for metastatic HER2-positive BC through a network meta-analysis of clinical trial data. METHOD: The PubMed, Embase, and Cochrane Library databases and abstracts from ASCO, ESMO, and WCLC were searched up to March 16, 2023. Eligible randomized controlled trials (RCTs) were selected to analyze the progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and grade 3 or higher adverse events (≥3AEs). Fourteen treatment regimens were ranked using the network meta-analysis and the surface under the cumulative ranking curve. RESULTS: Nineteen RCTs with 3,887 participants were analyzed. The taxane or paclitaxel or docetaxel + trastuzumab + pyrotinib (THPyr) regimen demonstrated the most significant PFS benefit, followed by the taxane or paclitaxel or docetaxel + trastuzumab + pertuzumab (THP) regimen. Regarding the ORR, THPyr ranked the highest, followed by THP and trastuzumab emtansin + pertuzumab (TdmP). THP offered the most favorable OS benefit. THPyr was effective in patients with HER2 3 + and hormone receptor-negative and positive status. No significant differences in safety and ≥3AEs were observed between the THPyr and other regimens. CONCLUSION: The THPyr regimen might be optimal as initial treatment for patients with advanced HER2-positive BC and is likely to be approved as a new first-line treatment option.
Effect of radical radiotherapy dose on the prognosis of limited-stage thoracic small cell carcinoma of the esophagus: A multicenter retrospective trial from China (CHiSCEC).
Li Z, Zhang Q, Wang Q … +16 more , Zhang Y, Wang Y, Shen W, Zhang W, Ge X, Su X, Yang N, Li L, Ma J, Zhao L, Tan B, Dong W, Zhang J, Sun D, Sun H, Huang W
J Cancer Res Ther · 2025 Sep · PMID 40905869 · Publisher ↗
BACKGROUND: The optimal radiation dose for the treatment of small cell carcinoma of the esophagus (SCEC) has not been established. This study aimed to investigate the treatment outcomes and toxicities in patients with li...
BACKGROUND: The optimal radiation dose for the treatment of small cell carcinoma of the esophagus (SCEC) has not been established. This study aimed to investigate the treatment outcomes and toxicities in patients with limited-stage SCEC (LS-SCEC) treated by radiotherapy. METHODS: Patients with LS-SCEC from 14 institutions were retrospectively identified between December 2000 and October 2021. The primary endpoints of the study included overall survival (OS), progression-free survival (PFS), and local regional control (LRC), and the secondary endpoints were treatment-related toxicity parameters. Patients were categorized into a high-dose (HD, ≥ 60 Gy) group and low-dose (LD, <60 Gy) group based on the radiation dose. Additionally, they were classified into two groups based on the treatment sequence: concurrent chemoradiotherapy (CCRT) and sequential chemoradiotherapy (SCRT). A 1:1 propensity score matching (PSM) approach was applied to balance the observable potential confounding factors between the groups. RESULTS: Of the 150 patients included in the study, 56 received LD, and 94 received HD radiotherapy. After 1:1 PSM, the OS, PFS, and LRC in the HD group were higher than those in the LD group; however, the difference was not statistically significant (P > 0.05). No significant differences in survival and the occurrence of treatment-related toxicity were observed between the CCRT and SCRT groups. CONCLUSIONS: Neither CCRT nor SCRT was significantly associated with longer survival in LS-SCEC when a higher radiation dose was selected. A lower radiation dose might be a preferable time-dose fraction scheme; however, additional studies are required to validate these findings.
Development and validation of a risk signature based on disulidptosis-related ferroptosis genes in ovarian cancer.
Sun Y, Liu L, Guo F … +3 more , Jin Z, Miao Y, Ma Y
J Cancer Res Ther · 2025 Sep · PMID 40905868 · Publisher ↗
BACKGROUND: Disulfidptosis and ferroptosis, newly identified forms of cell death, have attracted widespread attention; however, their relationship with ovarian cancer (OC) prognosis remains unclear. METHODS: We construct...
BACKGROUND: Disulfidptosis and ferroptosis, newly identified forms of cell death, have attracted widespread attention; however, their relationship with ovarian cancer (OC) prognosis remains unclear. METHODS: We constructed a multivariate Cox risk signature comprising three key genes: CREB3, PIEZO1, and SLC7A11. Patients were stratified into high- and low-risk groups based on the optimal cutoff value of the risk score. Subsequently, survival analysis was conducted in the training group (TCGA-OV) and external databases (GSE26712 and GSE63885), with the predictive efficiency of the risk signature evaluated through ROC curves. RESULTS: Prognosis was significantly better for patients in the low-risk group than in the high-risk group. Compared to single clinical features such as age and stage, the risk score had the highest diagnostic value for prognostic evaluation. Based on gene function and pathway analyses, differential genes were found to be related to oxidative stress. Immune infiltration analysis indicated that risk scores were associated with immunosuppressive cells such as M2 macrophages. Finally, the protein expression levels of the key gene CREB3 in OC tissues were evaluated in vitro. CONCLUSION: This study might provide significant value for exploring the relationship between disulfidptosis-related ferroptosis genes and OC, and its results may provide insights on new therapeutic targets for OC.
Comparing long-term survival prognosis with surgery-based systemic treatment of gastrointestinal stromal tumors: A population-based study.
Gao F, Xu X
J Cancer Res Ther · 2025 Sep · PMID 40905867 · Publisher ↗
BACKGROUND: To date, the optimal sequence of systemic therapy (ST) and surgical resection for gastrointestinal stromal tumors (GISTs) remains unknown. This study aimed to compare the long-term outcomes of different ST ap...
BACKGROUND: To date, the optimal sequence of systemic therapy (ST) and surgical resection for gastrointestinal stromal tumors (GISTs) remains unknown. This study aimed to compare the long-term outcomes of different ST approaches when combined with surgery. SUBJECT AND METHODS: Data on GISTs were retrospectively collected from the Surveillance, Epidemiology, and End Results database. The patients were divided into three groups: preoperative ST, postoperative ST, and their combination. The Cox proportional-hazards model was used to analyze risk factors for overall survival (OS) and cancer-specific survival (CSS). Furthermore, the Kaplan-Meier method was employed to compare survival differences in OS and CSS. To minimize the confounding factors, a 1:1:1 propensity score matching method was used. The results of the subgroup analyses were displayed using forest plots. RESULTS: Among the 3774 patients, 518 (13.7%) received preoperative ST, 2799 (74.2%) received postoperative ST, and 457 (12.1%) received combined therapy. The median survival times were 42, 60, and 41 months for the preoperative ST, postoperative ST, and combined therapy groups, respectively. Kaplan-Meier curves showed no significant differences in OS and CSS among the groups before and after matching. Cox regression analysis, with adjustment for variables, revealed no survival advantage among the groups. Subgroup analyses showed that male patients, patients with localized disease, and patients with a tumor size <75 mm could achieve an OS benefit from postoperative ST (P < 0.05). CONCLUSION: Surgery-based systemic therapies provide a comparable long-term survival prognosis for patients with GISTs. In addition, some patients may achieve an OS benefit from postoperative ST.
Comparison of postoperative adjuvant therapy for early-stage cervical cancer: A surveillance, epidemiology, and end results analysis.
Zhou L, Bai Y, Diao P … +2 more , Zeng S, Sun C
J Cancer Res Ther · 2025 Sep · PMID 40905866 · Publisher ↗
OBJECTIVES: To compare the effects of different adjuvant treatments for different pathological types of early-stage cervical cancer post-surgery. MATERIALS AND METHODS: Patients with International Federation of Gynecolog...
OBJECTIVES: To compare the effects of different adjuvant treatments for different pathological types of early-stage cervical cancer post-surgery. MATERIALS AND METHODS: Patients with International Federation of Gynecology and Obstetrics (FIGO) stages I-II squamous cell carcinoma (SCC), adenocarcinoma (ADC), and adenosquamous carcinoma (ASC) who underwent hysterectomy and postoperative radiotherapy (RT) from 2004 to 2015 in the surveillance, epidemiology, and end results program database were analyzed. The clinicopathological characteristics and survival rates were compared. RESULTS: A total of 5444 cases were included. ADC had the highest 5-year overall survival (OS) and cervical carcinoma-specific survival (CCSS) rates, followed by SCC and ASC. No significant difference in prognosis was noted among the three histological subtypes when treated with chemoradiation therapy (CRT). However, the survival benefit for ASC was significantly lower than that for SCC (hazard ratio [HR], 1.625; 95% confidence interval [CI], 1.024-2.579; P = 0.039) when treated with RT alone. The prognosis of FIGO stage I patients was significantly better with RT than with CRT (HR, 0.766; 95% CI, 0.622-0.943; P = 0.012). No significant differences in CCSS were observed between patients (stages I and II) treated with external beam RT (EBRT) and EBRT + intracavity brachytherapy. CONCLUSION: No significant differences in OS and CCSS were observed among the three histological subtypes. The prognosis of ASC patients who received CRT was better than that of those who received RT alone. Patients with stage I tumors could obtain better survival with RT alone. The addition of brachytherapy to EBRT yielded no benefits across the three histological subtypes.
Combination of hepatic artery infusion chemotherapy and PD1 immune checkpoint inhibitor improve survival in patients with KRAS-mutated unresectable colorectal liver metastases: A propensity score matching study.
Hu H, Gao F, Lin M … +3 more , Liu R, Chi J, Guo J
J Cancer Res Ther · 2025 Sep · PMID 40905865 · Publisher ↗
OBJECTIVE: This study examined the effect of hepatic arterial infusion chemotherapy (HAIC) plus programmed death 1 inhibitors (HAICPs) in patients with unresected colorectal cancer liver metastases (UCRLM) with and witho...
OBJECTIVE: This study examined the effect of hepatic arterial infusion chemotherapy (HAIC) plus programmed death 1 inhibitors (HAICPs) in patients with unresected colorectal cancer liver metastases (UCRLM) with and without KRAS mutations. MATERIALS AND METHODS: We retrospectively collected data from patients with UCRLM, who received HAIC with HAICP or HAIC alone (oxaliplatin plus fluorouracil), including information on KRAS status (mutated, MUT; wild-type, WT) from a multicenter institutional database. Propensity score matching (PSM) was performed. The associations of KRAS status, treatment, and clinicopathological features with outcomes were determined. Confounding factors were adjusted using the Cox proportional hazard model. RESULTS: A total of 668 patients (414 KRAS-WT, 254 MUT) were followed for a median of 4.6 years post-HAIC. Fifty-five percent received HAICP. Before PSM, patients in the HAICP group exhibited a significantly higher CEA level (P = 0.014), more tumor nodules (P = 0.012), lower clinical risk score (P = 0.009), and fewer extrahepatic metastases (P = 0.017). After PSM analysis, 260 pairs of patients were established. The 5-year progression-free survival (PFS) for patients treated with HAICP versus HAIC was 36% and 31%, respectively (hazard ratio, 0.64; 95% CI, 0.48-0.85; P = 0.008). The 5-year overall survival (OS) for patients treated with HAICP versus HAIC was 72% and 64%, respectively (hazard ratio, 0.44; 95% CI, 0.32-0.63; P < 0.001). In KRAS-WT tumors, the 5-year survival was 79% and 61% for patients treated with HAICP versus HAIC (P < 0.001), respectively. In KRAS-MUT tumors, the 5-year survival was 68% and 52% for patients treated with HAICP versus HAIC (P < 0.001), respectively. CONCLUSION: The combined application of HAICP is an effective regimen for treating patients with UCRLM. HAICP shows superior survival independent of KRAS mutation. In addition, HAICP ameliorates the poor survival observed among KRAS-MUT UCRLM cases.
Construction and application of a mortality risk prediction model for patients with lung squamous cell carcinoma: A competing risk analysis.
Wang Q, Wang Q, Wang D … +4 more , Lao J, Yang Y, Tang F, Zhang X
J Cancer Res Ther · 2025 Sep · PMID 40905864 · Publisher ↗
BACKGROUND: Lung squamous cell carcinoma (LUSC) is the dominant histological subtype of lung cancer, accounting for 30% of all cases. Most patients develop distant metastases by the time they are diagnosed with the disea...
BACKGROUND: Lung squamous cell carcinoma (LUSC) is the dominant histological subtype of lung cancer, accounting for 30% of all cases. Most patients develop distant metastases by the time they are diagnosed with the disease, owing to a delay in the appearance of symptoms. Therefore, accurate prognostic prediction is essential for personalized treatment. However, existing models tend to ignore competing risks, leading to an overestimation of the incidence. This study aimed to construct an accurate mortality risk prediction model for LUSC patients from the perspective of competing risks. METHODS: A total of 28,312 patients with LUSC from 2000 to 2019 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Potential predictors included age, sex, treatments, race, marital status, tumor site, differentiation, and stage. Statistical analyses were performed using cause-specific hazard and Fine-Gray risk models to assess competing risks. Model performance was evaluated using Harrell's concordance index and calibration plots. RESULTS: Age, sex, treatment, marital status, tumor site, differentiation, and stage significantly affected the prognosis of LUSC. Both risk models showed good predictive power. The Fine-Gray risk model was slightly better than the cause-specific hazard model in terms of the 3- and 5-year mortality. The key risk factors for LUSC outcomes included age, male gender, absence of surgery, chemotherapy or radiotherapy, being unmarried or divorced, primary tumors in the lower lobe or main bronchus, low differentiation, and high tumor stage. CONCLUSION: The Fine-Gray model excels in predicting LUSC death risk and holds significant clinical value.
Effectiveness and safety of percutaneous microwave ablation and radiofrequency ablation in the treatment of pulmonary metastasis: A systematic review and meta-analysis.
Xu J, Xie Q, Ye X
J Cancer Res Ther · 2025 Sep · PMID 40905863 · Publisher ↗
This study aimed to evaluate the efficacy and safety of percutaneous microwave ablation (MWA) versus radiofrequency ablation (RFA) for the treatment of pulmonary metastasis. A systematic literature search was conducted u...
This study aimed to evaluate the efficacy and safety of percutaneous microwave ablation (MWA) versus radiofrequency ablation (RFA) for the treatment of pulmonary metastasis. A systematic literature search was conducted using the PubMed, Embase, and Cochrane Library databases from their inception through October 2023. Studies comparing MWA and RFA for pulmonary metastasis were included. Meta-analysis was performed using Review Manager 5.4, incorporating a total of six articles comprising 1407 ablations.The complete ablation rate was significantly higher in the MWA group compared to the RFA group (OR: 2.41; 95% CI: 1.33-4.37; P = 0.004), and recurrence was markedly lower with MWA (OR: 0.27; 95% CI: 0.08-0.94; P = 0.04). However, no significant differences were observed between the two groups in terms of overall survival or major complications.MWA demonstrates superior efficacy to RFA in achieving complete ablation and reducing recurrence in the treatment of pulmonary metastasis, with comparable safety profiles between the two techniques.
Prognostic impact of Fusobacterium nucleatum on survival in colorectal cancer: A systematic review and meta-analysis.
Wang T, Lin S, Ji Y … +3 more , Puqiong C, Gao J, Li S
J Cancer Res Ther · 2025 Sep · PMID 40905862 · Publisher ↗
Recent studies have demonstrated a significant correlation between Fusobacterium nucleatum (F. nucleatum) and colorectal cancer. However, the prognostic significance of this microorganism in patients with colorectal canc...
Recent studies have demonstrated a significant correlation between Fusobacterium nucleatum (F. nucleatum) and colorectal cancer. However, the prognostic significance of this microorganism in patients with colorectal cancer remains unclear. This meta-analysis aimed to evaluate the impact of F. nucleatum on the overall survival of patients with colorectal cancer. A thorough literature search of PubMed, Embase, and Cochrane Library databases was conducted until December 2023. The hazard ratio (HR) with the corresponding 95% confidence interval (CI) was analyzed using Review Manager 5.4 software for survival outcomes, including the overall survival (OS). A total of 13 studies, covering 4475 samples with colorectal cancer, were selected based on specified inclusion and exclusion criteria. In the univariate and multivariate analyses, patients with positive or high abundance of Fusobacterium in the cancer tissues displayed poorer OS (univariate HR = 1.28, 95% CI: 1.08-1.53, P = 0.006; multivariate HR = 1.61, 95% CI: 1.37-1.88, P < 0.0001) than those with negative/low bacteria levels. Subgroup analysis revealed that Fusobacterium in cancer tissues was associated with tumor stage and differentiation. Patients with stage III and IV, T3 and T4, or poorly differentiated tumors had a higher abundance of Fusobacterium in cancer tissues than those with stage I and II, T1 and T2, or well-to-moderately differentiated tumors (P < 0.05). No statistically significant difference in lymph node metastasis was observed. These findings suggest that the Fusobacterium microbiome may play a significant role in predicting the survival outcomes in patients with colorectal cancer.
Research progress of dosiomics in precision radiotherapy.
Lei Y, Bai H, Yu J … +5 more , Zhang Z, Wang L, Li B, Wang L, Li L
J Cancer Res Ther · 2025 Sep · PMID 40905861 · Publisher ↗
Radiotherapy is a conventional method that plays an important role in the comprehensive treatment of tumors. However, it has inevitable side effects that may affect prognosis. Therefore, increasing attention has been pai...
Radiotherapy is a conventional method that plays an important role in the comprehensive treatment of tumors. However, it has inevitable side effects that may affect prognosis. Therefore, increasing attention has been paid to radiotherapy-related side effects and prognosis after radiotherapy. With the development of artificial intelligence, high-throughput extraction of quantitative features and correlation analysis of medical images have rapidly developed to improve tumor diagnosis, staging, grading, and personalized treatment. In recent years, there has been growing interest in the use of machine learning models to predict the effects of radiotherapy based on three-dimensional dose distribution maps generated by optimizing radiotherapy plans, which contain dose features or dosiomics that reveal the dose-response relationship of organs and treatment. The use of machine learning modeling to describe the advantages and accuracy of dosiomics in predicting the toxicity and prognosis of radiotherapy has laid a foundation for personalized radiotherapy. This paper aimed to review the achievements of past dosiomics research, introduce the latest advancements in clinical radiotherapy, and discuss the value and future direction of dosiomics in personalized radiotherapy.
Side effects of boron neutron capture therapy.
Zhang Y, Cheng Y
J Cancer Res Ther · 2025 Sep · PMID 40905860 · Publisher ↗
Boron neutron capture therapy (BNCT) is an innovative cancer treatment modality that selectively eliminates tumor cells while sparing normal tissues. Clinical studies have explored its application across various malignan...
Boron neutron capture therapy (BNCT) is an innovative cancer treatment modality that selectively eliminates tumor cells while sparing normal tissues. Clinical studies have explored its application across various malignancies, including malignant gliomas, meningiomas, pediatric tumors, head and neck cancers, and melanomas. However, despite its therapeutic potential, BNCT is associated with various adverse effects that differ depending on the tumor type, neutron source, boron delivery agent, and treatment protocol. These adverse reactions pose significant challenges to the broader clinical implementation of this approach. This review systematically examines the adverse effects of BNCT observed in clinical studies, focusing on their underlying mechanisms, contributing factors, and tumor-specific variations. Additionally, it highlights current strategies for managing and preventing these effects and emphasizes the need for further research to address unresolved challenges. This article aims to provide comprehensive insights into the adverse effects of BNCT, supporting the development of safer and more effective treatment protocols and ultimately advancing their role in precision oncology.
Current trends in media and their role in cancer care.
Kapoor R, Ray MD
J Cancer Res Ther · 2025 Apr · PMID 40616571 · Publisher ↗
Abstract loading — click title to view on PubMed.
Squamous cell carcinoma of vulva during pregnancy- A rare case report with review of literature.
Singla S, Goyal LD
J Cancer Res Ther · 2025 Apr · PMID 40616570 · Publisher ↗
Vulval carcinoma accounts for just 4% of all gynecological malignancies. It rarely occurs in women under the age of 40 years and diagnosis during pregnancy is extremely rare. This is a case of vulval carcinoma in a 31-ye...
Vulval carcinoma accounts for just 4% of all gynecological malignancies. It rarely occurs in women under the age of 40 years and diagnosis during pregnancy is extremely rare. This is a case of vulval carcinoma in a 31-year-old multiparous woman diagnosed in the third trimester of pregnancy and had successful pregnancy outcome. There are no clear recommendations on management of vulvar cancer during pregnancy. However surgical resection and lymphadenectomy during pregnancy has comparable outcomes to that observed in non-pregnant women.
Pemphigus vulgaris following radiotherapy in head and neck cancer: Clinicopathological perspective of a rare cutaneous manifestation after radiotherapy treatment.
Das S, Tiwari A, Asati D … +4 more , Walke VA, Gupta M, Kharade V, Pasricha R
J Cancer Res Ther · 2025 Apr · PMID 40616569 · Publisher ↗
Pemphigus vulgaris triggered by the radiotherapy is rare and very few cases have been reported in the literature. Lesions within the radiotherapy field can be difficult to differentiate from post radiation dermatitis. Th...
Pemphigus vulgaris triggered by the radiotherapy is rare and very few cases have been reported in the literature. Lesions within the radiotherapy field can be difficult to differentiate from post radiation dermatitis. Though exact pathogenesis is not understood, radiotherapy induced immunomodulation leading to bullous skin lesions, is thought to be critical. Here we present the clinicopathological perspective of pemphigus vulgaris involving the skin within and outside the radiotherapy portal, presented 2 weeks after the completion of radiotherapy. The condition requires multidisciplinary management and close coordination between oncologist, dermatologist, and dermatopathologist. Diagnosis is established based on the clinical presentation, histopathology, and direct immunofluorescence examination. Early institution of immunosuppressive therapy can improve the skin lesions and reduce the morbidity significantly.
Case report of an adult with rhabdomyosarcoma of lung with ovarian metastases or the other way around: Do's and don'ts with review of literature.
Jassal T, Kharade V, Das S … +1 more , Gupta M
J Cancer Res Ther · 2025 Apr · PMID 40616568 · Publisher ↗
Primary pulmonary rhabdomyosarcoma (RMS) is extremely rare (0.07%) in persons aged >45 years and is frequently misdiagnosed as small-cell lung cancer. Little information is available regarding the management of patients,...
Primary pulmonary rhabdomyosarcoma (RMS) is extremely rare (0.07%) in persons aged >45 years and is frequently misdiagnosed as small-cell lung cancer. Little information is available regarding the management of patients, with available literature only limited to a few case reports. We report a rare case of RMS of the lung with multiple metastases with an extensive literature review on the subject. A 52-year-old woman presented with shortness of breath, orthopnea, and chest pain for one and a half months. She also developed abdominal distension in the last month. Imaging showed a large, ill-defined solid cystic mass arising from the retroperitoneum abutting the urinary bladder with multiple adjacent small nodular deposits in serosa and peritoneum with gross ascites along with two large mass lesions in the lower lobe of the left lung and bilateral lung parenchymal metastatic deposits. The biopsy of the adnexal and lung lesions was performed along with immunohistochemistry, which was suggestive of rhabdomyosarcoma. The patient was planned for palliative chemotherapy with biweekly vincristin, adriamycin, cyclophosphamide/ifosphamide, etoposide (VAC/IE) regimen with prophylactic granulocyte-colony stimulating factor support followed by response assessment after 3-4 cycles. However, dose-compressed VAC/IE is highly myelosuppressive and lead to febrile neutropenia in our patient and thus culminated in her death. Hence, the Indian patients should be challenged with dose-compressed VAC/IE with extreme caution. Three-weekly IE/VAC regimen is an alternative.
Multidisciplinary approach to the challenges in the perioperative management of large merkel cell carcinoma.
Sharma J, Walia HS, Saini V … +3 more , Guru A, Mitra LG, Gulia A
J Cancer Res Ther · 2025 Apr · PMID 40616567 · Publisher ↗
An integrated multidisciplinary team-based approach to patients from the moment surgery is contemplated through to full recovery is the essence of perioperative care. The management of large soft tissue masses in the bac...
An integrated multidisciplinary team-based approach to patients from the moment surgery is contemplated through to full recovery is the essence of perioperative care. The management of large soft tissue masses in the back is very challenging with multiple facets requiring precision care and erudite planning. Our Case of Merkel Cell carcinoma is an excellent manifestation of such a complex scenario. A multidisciplinary approach with closed-loop communication is essential in countering the challenges with the need for tailoring management for Immunotherapy and its complications, huge mass with areas of necrosis leading to sepsis, difficulty in mask ventilation and intubation due to limited posture, very poor vascular access, the need of rapid infuser for resuscitation, cardiac output and pulse pressure variation for hemodynamic monitoring, challenges with prone position intraoperatively with complex plastic surgery reconstruction and extubation in the lateral decubitus position.
Duodenal obstruction secondary to metastatic breast cancer.
O'Neill RS, Field A, Kim BSM … +3 more , Ferguson JS, Ghaly S, Dear RF
J Cancer Res Ther · 2025 Apr · PMID 40616566 · Publisher ↗
Breast cancer is the most common malignancy affecting females and is a leading cause of cancer-related mortality worldwide. The most common sites of metastatic disease are bone, liver, lung and brain, with the gastrointe...
Breast cancer is the most common malignancy affecting females and is a leading cause of cancer-related mortality worldwide. The most common sites of metastatic disease are bone, liver, lung and brain, with the gastrointestinal tract less commonly implicated. Intestinal metastasis from breast cancer is rare, with vast majority of patients being asymptomatic. Diagnosis can often be delayed due to gastrointestinal symptoms perceived to be secondary to treatment rather than malignancy. Unfortunately, intestinal metastasis is associated with a poor prognosis with the median survival being 12 months. We present the case of a 53-year-old female with a diagnosed history of metastatic breast cancer who presented to our institution with nausea, vomiting and abdominal pain and was subsequently diagnosed with a small bowel obstruction secondary to duodenal metastasis after endoscopic ultrasound-guided tissue acquisition. She was managed conservatively with chemotherapy resulting in resolution of her small bowel obstruction.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe